Connor Clark & Lunn Investment Management Ltd. Makes New $643,000 Investment in REGENXBIO Inc. (NASDAQ:RGNX)

Connor Clark & Lunn Investment Management Ltd. acquired a new stake in REGENXBIO Inc. (NASDAQ:RGNX) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 61,288 shares of the biotechnology company’s stock, valued at approximately $643,000. Connor Clark & Lunn Investment Management Ltd. owned approximately 0.12% of REGENXBIO at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of RGNX. Maryland State Retirement & Pension System grew its stake in REGENXBIO by 7.2% in the second quarter. Maryland State Retirement & Pension System now owns 15,800 shares of the biotechnology company’s stock valued at $185,000 after purchasing an additional 1,067 shares in the last quarter. Amalgamated Bank grew its stake in shares of REGENXBIO by 9.9% in the second quarter. Amalgamated Bank now owns 13,613 shares of the biotechnology company’s stock valued at $159,000 after buying an additional 1,227 shares in the last quarter. Price T Rowe Associates Inc. MD increased its holdings in REGENXBIO by 8.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 18,177 shares of the biotechnology company’s stock worth $383,000 after buying an additional 1,438 shares during the last quarter. Arizona State Retirement System raised its position in REGENXBIO by 20.6% during the second quarter. Arizona State Retirement System now owns 11,669 shares of the biotechnology company’s stock worth $137,000 after acquiring an additional 1,997 shares in the last quarter. Finally, nVerses Capital LLC lifted its stake in REGENXBIO by 183.3% in the third quarter. nVerses Capital LLC now owns 3,400 shares of the biotechnology company’s stock valued at $36,000 after acquiring an additional 2,200 shares during the last quarter. Institutional investors and hedge funds own 88.08% of the company’s stock.

REGENXBIO Trading Up 4.8 %

Shares of RGNX opened at $10.01 on Friday. The stock’s 50-day moving average price is $10.06 and its two-hundred day moving average price is $11.91. REGENXBIO Inc. has a 12 month low of $8.53 and a 12 month high of $28.80. The company has a market capitalization of $495.90 million, a PE ratio of -1.99 and a beta of 1.23.

Insider Transactions at REGENXBIO

In related news, Director Argeris N. Karabelas sold 10,000 shares of REGENXBIO stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $10.11, for a total transaction of $101,100.00. Following the completion of the transaction, the director now owns 11,286 shares of the company’s stock, valued at $114,101.46. This trade represents a 46.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 13.13% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the stock. StockNews.com upgraded shares of REGENXBIO from a “sell” rating to a “hold” rating in a research note on Friday, September 20th. Morgan Stanley reissued an “overweight” rating and set a $22.00 price target on shares of REGENXBIO in a research report on Friday, November 15th. Raymond James reaffirmed an “outperform” rating and issued a $18.00 price objective on shares of REGENXBIO in a research report on Thursday, October 10th. HC Wainwright decreased their target price on REGENXBIO from $40.00 to $36.00 and set a “buy” rating on the stock in a report on Thursday, November 21st. Finally, Barclays cut their price target on REGENXBIO from $55.00 to $50.00 and set an “overweight” rating for the company in a report on Monday, August 5th. Two research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $35.27.

REGENXBIO Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.